Evotec (ETR:EVT) Stock Price Breaks Above 50 Day Moving Average – Here’s Why

Evotec SE (ETR:EVT) crossed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of €2.90 and traded as high as €3.17. Evotec shares last traded at €3.09, with a volume of 2,451,951 shares trading hands.

Evotec Stock Performance

The firm has a market capitalization of $587.06 million, a PE ratio of -3.11, a price-to-earnings-growth ratio of 0.98 and a beta of 1.27. The company has a debt-to-equity ratio of 65.02, a quick ratio of 2.97 and a current ratio of 2.32. The company’s fifty day moving average price is €2.90 and its two-hundred day moving average price is €4.34.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic.